Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01153750
Recruitment Status : Completed
First Posted : June 30, 2010
Last Update Posted : June 30, 2010
Information provided by:
University Hospital Dresden

Brief Summary:
To test the efficacy of a combination chemotherapy of imatinib and 5-FU in advanced or metastatic cholangiocellular carcinoma.

Condition or disease Intervention/treatment Phase
Advanced or Metastatic Cholangiocellular Carcinoma and Bile Duct Drug: Glivec Phase 2

Detailed Description:

Efficacy: Tumor assessments should be performed by a CT or MRI scan, throughout the study. All assessments should be performed within 14 days of the scheduled day according to the visit schedules, and whenever clinically indicated otherwise. Radiological studies must use the same techniques as used at baseline. Evaluation will be based on RECIST criteria.

Safety: Safety assessments will consist of evaluating adverse events and serious adverse events, laboratory parameters including hematology, chemistry, vital signs, physical examinations, and documentation of all concomitant medications and/or therapies.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study to Evaluate the Efficacy of a Chemotherapy Combination With Imatinib (Glivec®) and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct
Study Start Date : April 2007
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Arm Intervention/treatment
Experimental: Glivec and 5-Fluorouracil/Leucovorin
All patients will receive Glivec® 600 mg once daily without dose escalation. Glivec® will be given on day -4, -3, -2, -1, 1, 2, 3 and 4. There will be no day "0". Patients will also receive 5-FU (2000mg/qm 24hc.i. d1 + d2) and leucovorin (200mg/qm 2h-infusion) qd15.
Drug: Glivec

Primary Outcome Measures :
  1. Disease Control Rate (DCR)

Secondary Outcome Measures :
  1. Progression-free survival (PFS)
  2. Response rate (RR)
  3. Overall survival
  4. Toxicity
  5. Evaluation of molecular predictive markers for response and toxicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically/Cytologically confirmed diagnosis of advanced / metastatic carcinoma of the gallbladder or bile duct, which is unresectable or metastatic and therefore incurable with any conventional multimodality approach
  • Performance status 0, 1 or 2 (ECOG)
  • Written, voluntary informed consent
  • Age > 18 years
  • Adequate bone marrow function (Granulocytes > 1,5 x 109/l, Hb > 10 g/dl, Platelets > 100 x 109/l)
  • Adequate hepatic and renal function ( bilirubin < 1,25 x upper normal limit or < 1,5 x upper normal limit if hyperbilirubinemia is related to underlying disease, ALAT + ASAT < 1,5 x upper normal limit, in case of liver metastases < 5 x upper normal limit, creatinine < 1,25 x upper normal limit)
  • Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Female patients with child-bearing potential must perform a highly effective barrier method of birth control throughout the study with a proven efficacy of >99%. The contraception treatment should be performed for an additional six month following discontinuation from study treatment. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following discontinuation of study drug.

Exclusion Criteria:

  • Patient has received any other investigational agents within 28 days of first day of study drug dosing.
  • Patient is < 5 years free of another primary malignancy, except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ.
  • Female patients who are pregnant or breast-feeding.
  • Patient has a severe and/or uncontrolled medical disease.
  • The concurrent use of warfarin or acetaminophen are not allowed with imatinib mesylate and need to be replaced by other medications (e.g. by low molecular heparins in case of warfarin).
  • Radiotherapy or any major abdominal or thoracic surgery < 4 weeks before study entry (excluding diagnostic biopsy or port implantation)
  • Patient has received neoadjuvant imatinib mesylate or fluoropyrimidines prior to study entry
  • Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
  • Known incompatibility of imatinib,5-FU, or leucovorin
  • Known brain metastases
  • Concurrent systemic chemotherapy, immunotherapy, hormone therapy
  • History of severe psychiatric illness
  • Drug- or alcohol abuse
  • Patient has know chronic liver disease (i.e., chronic active hepatitis, and cirrhosis)
  • Patients with dihydropyrimidine dehydrogenase deficiency (i.e. Treatment with Zostex)
  • Patients that are associated with or dependent of the investigator or sponsor
  • Patients with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
  • Patients with a creatinine clearance of < 50ml/min.
  • Patients with a severe decrease of bone marrow function
  • Patients with acute infections
  • Patients with severe decrease of liver function
  • Patients in reduced performance status (ECOG > 2)
  • No active vaccinations should be performed while being on study treatment
  • Anemia caused by vitamin B12 deficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01153750

Krankenhaus Nordwest
Frankfurt/ Main, Hessen, Germany, 60488
University Hospital
Dresden, Saxony, Germany, 01307
University Hospital Schleswig-Holstein, Campus Kiel
Kiel, Schleswig-Holstein, Germany, 24105
Onkologische Schwerpunktpraxis Eppendorf
Hamburg, Germany, 20249
Staedtisches Klinikum Magdeburg
Magdeburg, Germany, 36130
Johannes-Gutenberg-Universität Mainz, Medical Department I
Mainz, Germany, 55131
Ruppiner Kliniken GmbH
Neuruppin, Germany, 16816
Praxisgemeinschaft Dr. Hancken und Partner
Stade, Germany, 21680
Sponsors and Collaborators
University Hospital Dresden
Principal Investigator: Jan Stoehlmacher, PD Dr. University Hospital Dresden

Responsible Party: PD Dr. Jan Stoehlmacher, University Hospital Dresden, Medical Department I Identifier: NCT01153750     History of Changes
Other Study ID Numbers: TUD-Glivec-012
First Posted: June 30, 2010    Key Record Dates
Last Update Posted: June 30, 2010
Last Verified: April 2010

Keywords provided by University Hospital Dresden:
cholangiocellular carcinoma
bile duct cancer

Additional relevant MeSH terms:
Gallbladder Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Biliary Tract Diseases
Digestive System Diseases
Gallbladder Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action